Moreover, mutated p53 have exhibited oncogenic properties and negative chemo-resistance effects as tumors with mutated p53 showed poor response to cancer therapy in lung and prostate cancers (Robles and Harris, 2009). The gene discussed is TP53; the disease is prostate carcinoma.